Intercept Pharma (ICPT) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports First Quarter 2020 Financial Results, and Provides Business Update
May 11, 2020 7:00 AM EDTWorldwide Ocaliva net sales of $72.7 million in the first quarter 2020, representing 40% growth over the prior year quarterÂ
Regulatory and commercial preparations on track for tentatively scheduled FDA advisory committee meeting and post-approval launch of OCA in liver fibrosis due to NASHÂ
Company response to COVID-19 intended to ensure business continuity and support supply chain, clinical development and launch readiness activitiesÂ
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) --... More
